Tonix's 15min chart shows MACD Death Cross and KDJ Death Cross.

Based on the 15-minute chart for Tonix, two significant technical indicators have been triggered: the Moving Average Convergence Divergence (MACD) Death Cross and the KDJ (KST Divergence J) Death Cross on July 7, 2025 at 09:45. This suggests that the stock price may continue to decline, as the momentum of the stock price is shifting towards the downside, potentially leading to further decreases.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has announced the publication of a peer-reviewed study in the journal Cancer Cell, highlighting positive preclinical data for its candidate, mTNX-1700, in gastric cancer animal models [1]. The study, conducted in collaboration with Columbia University’s Medical School, demonstrates that combining mTNX-1700 with an anti-PD1 antibody increases survival and reduces metastases compared to anti-PD1 treatment alone.

mTNX-1700, a fusion protein of murine trefoil factor-2 (mTFF2) and murine serum albumin (MSA), activates cancer-killing CD8+ T cells and limits neutrophil-mediated immune evasion. The study suggests that fine-tuned modulation of CXCR4 can dismantle neutrophil-driven immune suppression and revive checkpoint efficacy without compromising normal myelopoiesis [1].

The human version of TNX-1700, which is under development for gastric and colorectal cancers, shows promise in overcoming resistance to anti-PD1 immunotherapy. The study shows that in several mouse models, mTNX-1700 plus anti-PD1 shrank primary tumors, cut liver and lung metastases, and increased survival compared to anti-PD-1 alone [1].

Tonix Pharmaceuticals, a fully-integrated biopharmaceutical company, is focused on transforming therapies for pain management, vaccines for public health challenges, and central nervous system disorders. The company is also developing TNX-102 SL for the management of fibromyalgia, which has been granted Fast Track designation by the FDA [1].

Technical Indicators for Tonix Pharmaceuticals

Based on the 15-minute chart for Tonix, two significant technical indicators have been triggered: the Moving Average Convergence Divergence (MACD) Death Cross and the KDJ (KST Divergence J) Death Cross on July 7, 2025 at 09:45. This suggests that the stock price may continue to decline, as the momentum of the stock price is shifting towards the downside, potentially leading to further decreases.

References

[1] https://www.biospace.com/press-releases/tonix-pharmaceuticals-announces-peer-reviewed-publication-in-cancer-cell-journal-highlighting-positive-preclinical-data-of-mtnx-1700-in-gastric-cancer-animal-models